Summit Therapeutics (SMMT) Q4 2025 earnings summary

Executive summary

• Advanced clinical development of ivonescimab, a bispecific antibody targeting PD-1 and VEGF, with multiple global Phase III trials in NSCLC, CRC, and other solid tumors underway or completed, and positive data supporting expansion into new indications.

• BLA for ivonescimab in EGFR-mutant NSCLC accepted by FDA, with a PDUFA target date of November 14, 2026.

• Commercial readiness activities ramping up in anticipation of potential US approval, with manufacturing process successfully transferred to a US-based facility.

• Expanded collaborations with GSK, Revolution Medicines, and GORTEC, with new combination studies and patient dosing milestones achieved; ILLUMINE Phase III study in head and neck cancer to begin enrollment in early Q2 2026.

• Over 4,000 patients dosed in clinical trials and more than 60,000 commercial patients in China.

Financial highlights

• Year-end 2025 cash and short-term investments of $713.4 million, up from $412.3 million at year-end 2024, with no debt.

• Q4 2025 GAAP operating expenses were $225 million, down from $234.2 million in Q3 2025; full-year 2025 GAAP operating expenses surged to $1,094.4 million, mainly due to $681.4 million in stock-based compensation.

• Q4 2025 non-GAAP operating expenses were $113.3 million, up from $103.4 million in Q3 2025; full-year 2025 non-GAAP operating expenses increased to $362.0 million.

• GAAP net loss was $1,079.6 million ($1.44/share) in 2025; non-GAAP net loss was $347.2 million ($0.46/share) in 2025.

• Significant stock-based compensation adjustments in both R&D and G&A expenses.

Outlook and guidance

• Interim PFS analysis for HARMONi-3 squamous cohort expected in Q2 2026; final PFS and interim OS data in H2 2026.

• HARMONi-3 non-squamous cohort enrollment to complete in H2 2026, with final PFS data anticipated in H1 2027.

• Continued expansion of the clinical pipeline, including new Phase III studies and novel combination regimens in 2026.

• GSK and Revolution Medicines collaborations to initiate new combination trials in mid-2026.